INTS (Intensity Therapeutics, Inc. Common stock) Stock Analysis - Hedge Fund Holdings
Intensity Therapeutics, Inc. Common stock (INTS) is a publicly traded Healthcare sector company. As of May 21, 2026, INTS trades at $4.63 with a market cap of $12.38M and a P/E ratio of -0.54. INTS moved +0.87% today. Year to date, INTS is -53.23%; over the trailing twelve months it is -55.35%. Its 52-week range spans $4.50 to $100.00. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces INTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns INTS stock?
Hedge funds tracked by Rallies that own INTS include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Intensity Therapeutics, Inc. Common stock.
INTS Key Metrics
Key financial metrics for INTS
Metric
Value
Price
$4.63
Market Cap
$12.38M
P/E Ratio
-0.54
EPS
$-8.56
Dividend Yield
0.00%
52-Week High
$100.00
52-Week Low
$4.50
Volume
0
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-11.61M
Gross Margin
0.00%
Top Hedge Funds Holding INTS
Citadel Advisors holds 14.96K shares of INTS, changed +0.00% as of Dec 31, 2024.
Hedge funds tracked by Rallies that own INTS include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Intensity Therapeutics, Inc. Common stock.
Does Rallies show 13F holders for INTS?
Yes. Rallies tracks hedge fund and 13F ownership data for INTS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INTS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INTS. It does not provide personalized investment advice.
